A quality-by-design optimized LC method for navigating degradation kinetics and quantification of favipiravir in the presence of degradation products and manufacturing impurities.

ABSTRACT: Emergent viruses require effective treatment regimens, and the severe acute respiratory syndrome coronavirus-2 variants are still evolving. Favipiravir has emerged as an effective antiviral medication, especially after its popularity against COVID-2019. Despite its growing popularity, favipiravir has not yet been included in any pharmacopeia, and new dosage forms are being developed to improve its bioavailability for various infections. Therefore, studying its stability and developing methods capable of detecting its impurities and degradation products are essential. An isocratic high-performance liquid chromatography with photodiode array detection method was also designed using the Quality-by-Design approach and validated to determine favipiravir in presence of its hydrolytic degradation

SUBMITTER: Ibrahim AE 

PROVIDER: S-EPMC12357339 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature